This trial is active, not recruiting.

Conditions osteoporosis, cognitive decline
Treatments vitamin b12, folic acid, vitamin d3, placebo (vitamin d3) - 600 iu per day
Phase phase 1
Sponsor Wageningen University
Collaborator ZonMw: The Netherlands Organisation for Health Research and Development
Start date September 2008
End date March 2013
Trial size 3000 participants
Trial identifier NCT00696514, NTR1333, ZonMw 6130.0031


It is hypothesized that vitamin B12 and folic acid supplementation reduces the number of incident fractures. The proposed study, a randomized placebo-controlled intervention trial, compares daily supplementation with folic acid (400 mcg) and vitamin B12 (500 mcg) to a placebo for a period of two years or longer in 3000 men and women aged 70 years and older, with initial basal plasma total homocysteine (tHcy) levels >= 15 micromol/L. Fracture incidence and time to fracture will be assessed and used as the efficacy measure.

Metabolic studies in a sub sample of the population will be included aiming to contribute to an understanding of the biological mechanisms underlying the associations found between markers of B-vitamin status and bone quality.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose prevention
(Placebo Comparator)
placebo capsule, once per day
placebo (vitamin d3) - 600 iu per day
600 IU vitamin D3 in one capsule, once per day
Vitamin B12 and folic acid capsule, once a day
vitamin b12, folic acid, vitamin d3
500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day

Primary Outcomes

time frame: two years

Secondary Outcomes

Cognitive decline
time frame: two years
Bone health
time frame: two years
Physical performance
time frame: two years
Quality of life
time frame: two years
Nutritional status
time frame: two years

Eligibility Criteria

Male or female participants at least 65 years old.

Inclusion Criteria: - 65 years and older; based on entry date into study; - Fasting plasma Hcy level >= 12 µmol/L and < 50 µmol/L; - No current or recent (<4 months) use of supplements with very high doses of B-vitamins; - Competent to make own decisions; - Persons with skin cancer are allowed to participate. - Compliance to tablet intake > 85% Exclusion Criteria: - Participation in other intervention trials; - Serious medical conditions, e.g. cancer diagnosis within the last 5 years or recent myocardial infarction; - Immobilization (bedridden, wheelchair bound);

Additional Information

Official title Vitamin B12 and Folic Acid Supplementation for Preventing Fractures in Elderly People
Principal investigator Lisette CPGM de Groot, Prof
Description Rationale: There is growing evidence that an elevated homocysteine level is a risk factor for fracture incidence. The most common cause of homocysteine elevation is poor vitamin B12 and folate status. It is hypothesized that supplementation with 500 µg vitamin B12 and 400 µg folic acid will reduce fracture incidence in elderly people Main objective: to determine the efficacy of oral supplementation with vitamin B12 and folic acid in the prevention of fractures Study design: The trial is a randomized double-blind placebo-controlled trial, with two arms in parallel (placebo versus supplement). The intervention comprises a period of two years, and will be targeted to 3000 elderly subjects with elevated homocysteine levels. The study will be performed in institutions or residences for older persons around Wageningen, Rotterdam and Amsterdam. Study population: 3000 elderly subjects (70 years and older) with elevated homocysteine levels Intervention (if applicable): One group receives daily a tablet with 500 µg vitamin B12 and 400 ug folic acid and the other group receives daily a placebo tablet. In both tablets 15 µg (600 IU) of vitamin D is included as well. Main study parameters/endpoints: Fracture incidence is the primary outcome measure Time to fracture will be calculated. It is expected that in the intervention group 34% less fractures will occur than in the placebo group. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: First, participants need to be recruited. This will be done via information letters. Those who are interested have to complete a small questionnaire and then they will receive an information brochure. Upon continued interest in the intervention study, participants will be invited for a blood sampling. This blood sampling will take place (nearby or) at the location where the participants live. Immediately after the blood sampling a run-in period will start. Blood will be checked on homocysteine levels. Only participants with elevated levels of homocysteine will be included in the study. Two to four weeks after the run-in period the intervention study will be implemented. At the start of this intervention study several measurements will be performed and several questionnaires will be completed together with the participant at home. During the whole study participants need to take daily one tablet and they have to complete calenders to monitor fracture incidence. At the end of the study, blood sampling will be performed and several measurements and questionnaires will be repeated again at home.
Trial information was received from ClinicalTrials.gov and was last updated in August 2011.
Information provided to ClinicalTrials.gov by Wageningen University.